Compare CHMI & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | ALDX |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.5M | 101.1M |
| IPO Year | N/A | 2014 |
| Metric | CHMI | ALDX |
|---|---|---|
| Price | $2.43 | $1.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $5.50 |
| AVG Volume (30 Days) | 133.3K | ★ 986.6K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 15.09% | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.13 | N/A |
| P/E Ratio | $139.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $1.07 |
| 52 Week High | $3.04 | $6.18 |
| Indicator | CHMI | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 28.02 | 39.25 |
| Support Level | $2.40 | $1.48 |
| Resistance Level | $2.46 | $1.88 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 2.62 | 47.44 |
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.